



Claims

1. A compound of formula (I)



or a pharmaceutically acceptable salt or polymorph thereof, wherein Y is (C₁₋₄) alkylene, R₁ is selected from the group comprising an imidazolyl, a pyrazolyl, a pyrrolyl, a furyl, an oxadiazolyl, an oxazolyl or a pyrimidyl each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, C₁₋₆ alkyl, C₁₋₄ alkoxy or C₃₋₆ cycloalkyl and R₂ is an aryl² or a heterocyclyl; wherein

the term "aryl²" includes phenyl, naphthyl, anthracenyl and phenanthrenyl, which is optionally substituted by one or more substituents independently selected from hydroxyl, C₁₋₆ alkyl, C₁₋₄ alkoxy, trifluoromethyl, CO₂R₃, R₄R₅N-C₁₋₄-alkyl-, halogen, hydroxyl- C₁₋₄ alkyl-, NR₆R₇, C(O)R₆, C(O)NR₆R₇, C₁₋₄alkyl-diethoxyphosphoryl or C₁₋₄alkyl-phosphonic acid, whereby R₃ is selected from H and C₁₋₆ alkyl, R₄ and R₅ taken together with the nitrogen, to which they are both attached, form a heterocycle selected from the group consisting of:



and R₆ and R₇ are each independently selected from H, C₁₋₆-alkyl or C₁₋₄alkoxy; wherein

the term "heterocyclyl" refers to tetrahydropyran and heteroaryl², whereby the term "heteroaryl²" includes pyridyl, tetrahydroisoquinoliny, imidazopyridinyl, quinoliny, isoquinoliny, pyrazinyl, pyrimidyl, naphthyridinyl, pyridazinyl, benzimidazolyl, benzothiazolyl, pyrazolyl, thiazolyl, imidazolyl, indazolyl, which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, C₁₋₆ alkyl, C₁₋₄ alkoxy, oxy-C₁₋₄alkylamine or pyrrolidinyl-methanone.

2. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or polymorph thereof according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.
- 5 3. A compound of formula (I) or a pharmaceutically acceptable salt or polymorph thereof according to claim 1, or a pharmaceutical composition according to claim 2 for use as a medicament.
- 10 4. Use of a compound of formula (I) or a pharmaceutically acceptable salt or polymorph thereof according to claim 1, or a pharmaceutical composition according to claim 2, in the manufacture of a medicament for the treatment of a disorder in which the modulation of TLR7 is involved.
- 15 5. Use of a compound of formula (I) or a pharmaceutically acceptable salt or polymorph thereof according to claim 1 in the manufacture of a medicament for the treatment of viral infections.